Altre lingue Medicenna Therapeutics Corp.

Azioni

MDNA

CA58490H1073

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:58:54 29/04/2024			Variaz. 5gg	Var. 1 gen.
2,31 ^CAD	-7,23%		+50,98%	+450,00%

24/04	Medicenna Therapeutics è salita del 13% dopo le presentazioni in calo	MT
16/04	Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Canadian Investment Regulatory Organization Trade Resumption - MDNA	26/04
Canadian Investment Regulatory Organization Trading Halt - MDNA	26/04
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management	26/04
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding	26/04
Medicenna Therapeutics Up 13% After Flagging Presentations	24/04
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting	24/04
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	10/04
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research	10/04
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR	10/04
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today	09/04
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine	09/04
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	09/04
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)	09/04
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	09/04
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	09/04
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)	09/04
Medicenna to Present at the 2024 Bloom Burton and Co. Healthcare Investor Conference	05/04
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	04/04
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting	06/03
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting	06/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Medicenna Therapeutics Corp.

Azioni

MDNA

CA58490H1073

Altre lingue

Filtri